Brief: Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology

Matinas BioPharma Holdings

07/12/2020 11:42

Dec 7 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES COLLABORATION WITH THE
NATIONAL
INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES TO EVALUATE ORAL
FORMULATIONS OF GILEAD’S ANTIVIRAL REMDESIVIR UTILIZING MATINAS’
LNC PLATFORM DELIVERY TECHNOLOGY
    * MATINAS BIOPHARMA - ANY PRODUCT GENERATED AS A PART OF
EFFORTS
BY MATINAS AND NIAID WOULD REQUIRE A LICENSE FROM GILEAD FOR USE
OF REMDESIVIR
    * MATINAS BIOPHARMA -  ANY PRODUCT GENERATED AS A PART OF
EFFORTS
BY MATINAS AND NIAID WOULD REQUIRE LICENSE FROM MATINAS FOR USE
OF LNC FORMULATION

Source text for Eikon:  ID:nGNX35q7Tm 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))